As of Wednesday close, Arcus Biosciences Inc.’s (NYSE:RCUS) stock was down -$0.09, moving down -0.45 percent to $20.09. The average number of shares traded per day over the past five days has been 1,239,180 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.94 fall in that time frame. In the last twenty days, the average volume was 944,755, while in the previous 50 days, it was 883,346.
Since last month, RCUS stock rose 2.97%. Shares of the company fell to $17.25 on 08/17/23, the lowest level in the past month. A 52-week high of $36.13 was reached on 08/23/23 after having rallying from a 52-week low of $15.70. Since the beginning of this year, RCUS’s stock price has dropped by -2.85% or -$0.59, and marked a new high 9 times. However, the stock has declined by -44.40% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
RCUS stock investors should be aware that Arcus Biosciences Inc. (RCUS) stock had its last reported insider trading activity 34 days ago on Jul 28. Jarrett Jennifer, the Chief Operating Officer of the company, disposed of 45,000 shares for $20.25 on Jul 28. It resulted in a $911,250 divestment by the insider. Azoy Alexander sold 1,018 shares at an average price of $20.41 on Jul 03. The insider now owns 11,596 shares following the transaction. On Jun 28, 10% Owner GILEAD SCIENCES, INC. bought 1,010,000 shares at $19.26 apiece. The transaction was valued at $19,452,600.
Valuation Metrics
The stock’s beta is 0.81. Besides these, the trailing price-to-sales (P/S) ratio of 12.53, the price-to-book (PB) ratio of 2.60.
Financial Health
In the three months ended June 29, Arcus Biosciences Inc.’s quick ratio stood at 5.50, while its current ratio was 5.50, showing that the company is able to pay off its debt. Based on annual data, RCUS earned $392.0 million in gross profit and brought in $112.0 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -42.80%. Return on equity (ROE) for the past 12 months was -45.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RCUS’s revenue rose 7.72% to $25.0 million during the quarter, while net income inched up to $29.0 million. While analysts expected Arcus Biosciences Inc. to report -$1.1 quarterly earnings, the actual figure was -$1.04 per share, beating the consensus estimate by 5.50%. During the quarter, the company generated -$85.0 million in EBITDA. The liabilities of Arcus Biosciences Inc. were 654.0 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $74.5 million.
Technical Picture
This quick technical analysis looks at Arcus Biosciences Inc.’s (RCUS) price momentum. With a historical volatility rate of 120.64%, the RSI 9-day stood at 49.56% on 30 August.
With respect to its five-day moving average, the current Arcus Biosciences Inc. price is down by -12.77% percent or -$2.94. At present, RCUS shares trade +4.96% above its 20-day simple moving average and +14.34% percent above its 100-day simple moving average. However, the stock is currently trading approximately +6.02% above its SMA50 and -28.07% below its SMA200.
Stochastic coefficient K was 41.69% and Stochastic coefficient D was 52.15%, while ATR was 1.41. Given the Stochastic reading of 34.55% for the 14-day period, the RSI (14) reading has been calculated as 50.95%. As of today, the MACD Oscillator reading stands at -0.14, while the 14-day reading stands at 0.90.
Analyst Ratings
BofA Securities launched its rating on Arcus Biosciences Inc. (NYSE: RCUS) to a Neutral in a note to investors on November 18, 2022. Arcus Biosciences Inc. (RCUS) has been rated Buy by analysts. According to 0 brokerage firms, RCUS is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Arcus Biosciences Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $41.00, the current consensus forecast for the stock is $21.00 – $70.00. Based on these forecasts, analysts predict Arcus Biosciences Inc. (RCUS) will achieve an average price target of $42.92.
